TNFSF10 and neoplasm: As expected, no decrease in tumour growth occurred, demonstrating that reduction of B-cell lymphomas by Jurkat-TRAIL is not due to any unspecific toxic side effects, but critically depends on intact death receptor signalling (Figure 5B, lower panel).